Coronary Disease articles

ACC 2022

ACC 2022 | FLAVOUR Study: FFR and IVUS in Intermediate Coronary Lesions

ACC 2022 | FLAVOUR Study: FFR and IVUS in Intermediate Coronary Lesions

FLAVOUR was a prospective randomized non-inferiority study in patients with intermediate coronary lesions (40%-70%) that compared two imaging modalities: IVUS (intravascular imaging) and FFR (fractional flow reserve).  According to this research—presented at ACC 2022—, FFR-guided angioplasty was non-inferior to IVUS-guided angioplasty at 2 years of follow-up. Furthermore, using FFR-based imaging led to fewer stent implantations.

ACC 2022

ACC 2022 | COMPLETE

Percutaneous coronary intervention improves angina related quality of life in AMI patients with multivessel disease. The COMPLETE study has shown patients receiving complete revascularization compared against culprit-only revascularization presented lower cardiovascular rate or AMI at 3-year followup. ACC featured a COMPLETE subanalysis assessing angina related quality of life.  It included 4041 patients, mean age 62,

ACC 2022

ACC 2022 | PACMAN AMI

Atherosclerosis plaque causing AMI is often large in volume, high in lipids and have a thin fibrous cap. Statins often reduce atherosclerosis progress, but the impact of PCSK 9 inhibitors (alirocumab) after acute coronary syndrome is scarcely known. The aim of this study was to determine the effect of alirocumab using intracoronary imaging (IVUS, OCT,

ACC 2022

ACC 2022 | IVVE

This randomized study aimed at assessing the flu vaccine vs placebo in patients with cardiac failure.  It included 5129 patients with cardiac failure randomized to receiving the flu vaccine annually for 3 years vs placebo.  Primary end point included cardiovascular death, non-fatal AMI, and stroke. There were no significant differences between both groups. However, pneumonia

ACC 2022

ACC 2022 | PROMPT-HF

Patients with cardiac failure with reduced ejection fraction (HFrEF) are sub treated when you look at guideline-directed medical therapy (GDMT).    The aim of this study was to assess if, using an electronic registry, we can alert treating physicians and optimize medical treatment.   100 healthcare professionals (doctors, nurses, etc) were randomized to receiving and alert

ACC 2022

ACC 2022 – EDIT-CMD

Roughly 40% of patients receiving a coronary angiography for stable angina (angina episodes twice a week despite medical treatment, lasting 3 months) do not present obstructive coronary artery disease (ANOCA). Between 60 to 90% is due to coronary vasomotor dysfunction (CVDys) which might be interpreted as vessel spasm or microvascular dysfunction.  A recent publication from

ACC 2022

ACC 2022 – Complete Trial QoL: Complete Revascularization in STEMI

The COMPLETE study has shown complete revascularization in STEMI reduces cardiovascular mortality or new AMI, which generated a change in ACC/AHA 2021 revascularization guidelines. However, its impact on quality of life is yet to be studied.  The aim of this prespecified analysis of the COMPLETE study is to determine whether complete revascularization improves quality of

Top